摘要
结直肠癌(CRC)是世界范围内最常见的癌症之一。抗肿瘤治疗的发展是在治疗直肠癌的主要挑战之一,它限制了通常的和有针对性的治疗方法在临床上的疗效。因此,了解支持抵抗力的机制是开发新的药物以扭转耐药性和更具体的有针对性的治疗的关键。越来越多的研究报道,microRNAs (miRNAs)是控制通过多种机制调节,赋予细胞的耐药表型而有内在或获得性耐药的癌细胞的关键参与者。microRNAs已经在各种CRC治疗和CRC干细胞干性(CRSCs)耐药调控中进化,依次调整对CRC细胞敏感性来进行抗癌治疗。靶向miRNA可能是根除CRSCs的一个新策略,重新使耐药细胞对抗癌药物敏感,提高药物的效力,发展治疗结直肠癌的新型生物制剂。本文强调了miRNAs在CRC耐药及CRSCs的调节作用,重点放在miRNAs怎样改变CRSCs死亡的引发机制,和上皮间质转化,在CRC细胞的细胞周期和凋亡的过程。
关键词: 肿瘤干细胞,耐药性,结直肠癌,microRNA,靶向治疗
图形摘要
Current Cancer Drug Targets
Title:MicroRNA as Regulators of Cancer Stem Cells and Chemoresistance in Colorectal Cancer
Volume: 16 Issue: 9
Author(s): Xiaoming Liu, Qi Fu, Yong Du, Yinxue Yang, William C. Cho
Affiliation:
关键词: 肿瘤干细胞,耐药性,结直肠癌,microRNA,靶向治疗
摘要: Colorectal cancer (CRC) is one of the most common cancers worldwide. The development of resistance to anti-cancer treatment is one of the major challenges in the treatment of CRC, which limits the efficacy of both conventional and targeted therapies in clinical settings. Understanding the mechanisms underpinning resistances is therefore critical in developing novel agents to reverse drug resistance and for more specific targeted treatments. Accumulating studies have reported that microRNAs (miRNAs) are key players in the regulation of cancer cells with intrinsic/acquired drug resistance through varied mechanisms that endow cells with a drug-resistant phenotype. miRNAs have been evolved in the regulation of chemoresistance to various CRC treatments and the stemness of CRC stem cells (CRSCs), sequentially modulating the sensitivity of CRC cells to anti-cancer treatments. Targeting miRNAs may be a novel strategy for eradicating CRSCs, re-sensitizing drug-resistant cells to anti-cancer agents, improving drug efficiency and developing novel biological agents for CRC treatment. This paper highlights the role of miRNAs in the regulation of chemoresistance and CRSCs in CRC, with focus on the mechanisms underlying how miRNAs alter CRSCs fate, and the process of epithelial-to-mesenchymal transition, cell cycle and apoptosis in CRC cells.
Export Options
About this article
Cite this article as:
Xiaoming Liu, Qi Fu, Yong Du, Yinxue Yang, William C. Cho , MicroRNA as Regulators of Cancer Stem Cells and Chemoresistance in Colorectal Cancer, Current Cancer Drug Targets 2016; 16 (9) . https://dx.doi.org/10.2174/1568009616666151118114759
DOI https://dx.doi.org/10.2174/1568009616666151118114759 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Review of Synthesis, Assay, and Prediction of β and γ-secretase Inhibitors
Current Topics in Medicinal Chemistry Overview of Cantharidin and its Analogues
Current Medicinal Chemistry Engineered Nanoparticles Against MDR in Cancer: The State of the Art and its Prospective
Current Pharmaceutical Design Advances in Regulating Tumorigenicity and Metastasis of Cancer Through TrkB Signaling
Current Cancer Drug Targets Tissue Protective and Anti-Fibrotic Actions of Suramin: New Uses of an Old Drug
Current Clinical Pharmacology Structural Findings and Molecular Modeling Approach of a TFPI-Like Inhibitor
Protein & Peptide Letters Targeting Phosphatidylserine in Anti-Cancer Therapy
Current Pharmaceutical Design Mitochondria-Mediated Oxidative Stress: Old Target for New Drugs
Current Medicinal Chemistry Chemosensitization and Immunosensitization of Resistant Cancer Cells to Apoptosis and Inhibition of Metastasis by the Specific NF-κB Inhibitor DHMEQ
Current Pharmaceutical Design The Insulin-Like Growth Factor (IGF) Signaling Pathway: Strategies for Successful Therapeutic Tasks in Cancer Treatment
Current Cancer Therapy Reviews Recent Progress in the Development of Quinoline Derivatives for the Exploitation of Anti-Cancer Agents
Anti-Cancer Agents in Medicinal Chemistry The Implications of Sortilin/Vps10p Domain Receptors in Neurological and Human Diseases
CNS & Neurological Disorders - Drug Targets The Prevention of Oral Mucositis in Patients with Blood Cancers: Current Concepts and Emerging Landscapes
Cardiovascular & Hematological Agents in Medicinal Chemistry Biological Agents Involved in Malignant Mesothelioma: Relevance as Biomarkers or Therapeutic Targets
Current Cancer Drug Targets Epigenetic Remodeling of Chromatin Architecture: Exploring Tumor Differentiation Therapies in Mesenchymal Stem Cells and Sarcomas
Current Stem Cell Research & Therapy Interleukin-6 Trans-Signaling and Colonic Cancer Associated with Inflammatory Bowel Disease
Current Pharmaceutical Design The Vitamin D Saga: Breaking Dawn
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) CCL21 and IFNγ Recruit and Activate Tumor Specific T cells in 3D Scaffold Model of Breast Cancer
Anti-Cancer Agents in Medicinal Chemistry Therapeutic Monoclonal Antibodies: Strategies and Challenges for Biosimilars Development
Current Medicinal Chemistry Lipid Nanoparticles to Deliver miRNA in Cancer
Current Pharmaceutical Biotechnology